Table 3.
Sensitivity and specificity of models based on different TMPRSS2:ETS fusion types to predict biopsy outcome
| Features | Pre-bx PSA1 | TMP:ERG I2 | Fx (III, IV, ETS)3 | All fusions4 |
| Frequency (%) | – | 27/92 (29.35) | 25/92 (27.17) | 32/92 (34.78) |
| Sensitivity (%) | 9/30 (23.1) | 17/39 (43.6) | 20/39 (51.3) | 21/39 (53.8) |
| Specificity (%) | 45/53 (84.9) | 43/53 (81.1) | 48/53 (90.6) | 42/53 (79.2) |
| Overall percentage | 58.7 | 65.2 | 73.9 | 68.5 |
| Odds ratio (OR) (95% CI) | 1.629 (0.960–2.763) | 3.323 (1.305–8.463) | 10.105 (3.315–30.808) | 4.455 (1.784–11.121) |
| P | 0.070 | 0.012 | <0.001 | 0.001 |
PSA, prostate-specific antigen.
1
Prebiopsy serum PSA (quantitative variable).
2
Any fusion-type event containing TMP:ERG subtype I fusion (categorical variable).
3
Any fusion-type event containing TMP:ERG subtype III or IV or other TMP:ETS (ETV1, ETV4, ETV5) (categorical variable).
4
Any fusion-type event containing TMP:ERG subtype I or III or IV or other TMP:ETS (ETV1, ETV4, ETV5) (categorical variable).